CLINICOPATHOLOGICAL STUDY ON RARE MALIGNANT TUMORS OF PAROTID GLAND AND COMPREHENSIVE REVIEW ON NEWER ENTITIES OF SALIVARY GLAND TUMORS

2021 ◽  
pp. 35-40
Author(s):  
Veena B Ganga ◽  
Krishnappa Krishnappa
Keyword(s):  
Salivary Gland ◽  
Malignant Tumors ◽  
Treatment Strategies ◽  
Salivary Gland Tumors ◽  
Term Survival ◽  
Comprehensive Review ◽  
Parotid Tumors ◽  
Time Period ◽  
Classi Cation

Salivary gland tumors are a heterogeneous group of tumors in the head and neck; most of the malignant tumors have a poor prognosis and limited long-term survival. The recent 2017 WHO classication had made few changes in the sub-categorization and modied some terms. More studies are underway in the eld of molecular level changes and responses to targeted therapies in these tumors. These researches have shown some resemblance in the behavior of salivary gland and breast carcinomas, leading to a new line of thinking in terms of hormonal therapy. This study outlines 14 cases of rare parotid tumors reported in our institute during the time period of 2018 to 2020 and a comprehensive review on salivary gland tumors, newer entities added, and newer treatment strategies.

scholarly journals Clinical Outcomes of Salivary Gland Tumor Surgery: A 10-year-chart View

2021 ◽  
Vol 12 (1) ◽  
pp. 11-14
Author(s):  
Sanjeev Mohanty ◽  
Vinoth Manimaran ◽  
Tejasvi Vemuru ◽  
Shiva Priya
Keyword(s):  
Salivary Gland ◽  
Submandibular Gland ◽  
Clinical Outcomes ◽  
Malignant Tumors ◽  
Histopathological Examination ◽  
Salivary Gland Tumor ◽  
Salivary Gland Tumors ◽  
Tumor Surgery ◽  
Gland Tumor ◽  
Parotid Tumors

ABSTRACT Background Salivary gland tumors constitute about 3% of all head and neck tumors. We present a series of 104 cases of various salivary gland pathologies and the various modalities of surgeries done between January 2007 and July 2017. Materials and methods Total 104 patients with salivary gland tumors were included in this study, of which 76 patients had parotid tumors and 28 were submandibular gland tumors. The presence or absence of coexisting salivary gland stones, involvement or noninvolvement of ducts were all considered. Preoperatively, patients underwent fine needle aspiration cytology (FNAC) and imaging studies along with routine blood investigations. Results All patients underwent surgery and subsequent histopathological examination (HPE). The preoperative FNAC and postoperative HPE were not correlating in 6.5% of parotid tumors and in 3.5% of submandibular gland tumor. Anomalies in the fasciovenous planes were seen in 3% of the patients, which caused intraoperative difficulties. Postoperatively, five patients had salivary leak and three patients had neuropraxia, which was managed conservatively and the patients recovered subsequently between 3 months and 6 months postoperatively. Conclusion Surgery for salivary gland tumors has its own threats due to the close proximity of nerve, vessels, and ducts. Postoperative complications like nerve palsy is seen more common in malignant tumors in both parotid and submandibular gland tumors. A proper methodical assessment and awareness of the various anatomical anomalies intraoperatively may give good surgical outcomes in surgeries of salivary gland tumors. In our study, various anomalies were encountered and dealt appropriately. How to cite this article Vemuru T, Mohanty S, Manimaran V, et al. Clinical Outcomes of Salivary Gland Tumor Surgery: A 10-year-chart View. Int J Head Neck Surg 2021;12(1):11–14.

Kaplan–Meier analysis of salivary gland tumors: prognosis and long-term survival

2019 ◽  
Vol 145 (8) ◽  
pp. 2123-2130
Author(s):  
Yair Israel ◽  
Adi Rachmiel ◽  
Konstantin Gourevich ◽  
Rafael Nagler
Keyword(s):  
Salivary Gland ◽  
Salivary Gland Tumors ◽  
Term Survival ◽  
Long Term Survival ◽  
Kaplan Meier

Malignant salivary gland tumors: A large single-institutional series evaluating long-term outcome

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 16523-16523
Author(s):  
S. Limaye ◽  
R. Dulala ◽  
R. Roy ◽  
A. Thomas ◽  
D. Janson ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Survival Data ◽  
Salivary Gland Tumors ◽  
Stage I ◽  
Treatment Modalities ◽  
Term Outcome ◽  
Term Survival ◽  
Long Term Outcome ◽  
Malignant Salivary Gland Tumors

16523 Background: Malignant salivary gland tumors comprise 3 to 6% of Head and Neck cancers. Long term survival data for salivary gland tumors are lacking. We undertook an analysis of all such patients treated at our institution over a 15 yr period. Methods: IRB approval was obtained for this retrospective analysis. Tumor registry data were reviewed for all adult patients diagnosed with salivary gland malignancies for the years 1990 - 2005. Age, Gender, Stage, histology, treatment modalities and survival data were recorded. Results: 200 patients were identified. Median age was 64 yrs (59–69). M:F ratio was 1:1.1 (M: 96; F: 104). Histology and stages: ( Table 1 )Mucoepidermoid Carcinoma (n=50), Adenoid Cystic Carcinoma (n=21), Acinar Cell Carcinoma (n=19), Adenocarcinoma (n=22; Stages: I= 7, II= 4, III= 3, IV= 8), Squamous (n= 12; Stages: I= 1, II= 3, III= 3, IV=5), Poorly Differentiated Carcinoma(n=10), Epithelial Myoepithelial Carcinoma (n=7), Malignant Mixed Carcinoma (n=4), Malignant Myoepithelioma (n=2), Carcinoma in Pleomorphic Adenoma (n=2) and Others (n=15). Hodgkin's and NHL (n=36).Treatment modalities: Surgery (S): n=88 (44%), Radiotherapy (RT): n=6 (3%); Chemotherapy (CT): n=6 (3%); S+RT: n =76(38%); S+CT: n=8 (4%); RT+CT: n =2(1%); S+RT+CT: n =4 (2%). Observation only : n=10(5%). Survival data (Med. survival and 5 yr OS respectively) for all histologies excluding lymphomas are: Stage I - 84 mos,93%; II - 93 mos,85%; III - 39 mos,60 %; IV - 24 mos, 40%. Survival data (Med survival and 5 yr OS) for lymphomas: Stage I - 55 mos,85%; II - 20 mos, 0%; III - 100 mos, 100%; IV- 48 mos, 25%. Median survival of all histology types excluding lymphoma by treatment: S=55 mos, S+RT= 60 mos, S+ CT= 56 mos, RT= 53 mos, RT+CT=15 mos, CT= 24 mos. Conclusions: This large series provides long term outcome data for a relatively rare group of HNCs. Long term survival is noted in several histological sub-types even in the setting of advanced disease. These data should help further define the natural history and biological behaviors of these tumors. [Table: see text] No significant financial relationships to disclose.

scholarly journals Epidemiologic Characteristics of Salivary Gland Tumors in an Iranian Population

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Nafise Shamloo ◽  
Alireza Ghanadan ◽  
Fahimeh Sadat Hashemian ◽  
Maedeh Ghorbanpour
Keyword(s):  
Salivary Gland ◽  
Adenoid Cystic Carcinoma ◽  
Salivary Glands ◽  
Pleomorphic Adenoma ◽  
Malignant Tumors ◽  
The Body ◽  
Salivary Gland Tumors ◽  
Benign Tumors ◽  
Cross Sectional ◽  
Adenoid Cystic

Background: Salivary gland tumors include a wide variety of benign and malignant tumors in the oral and maxillofacial region. Although these tumors are not common, they are not rare. The prevalence of these tumors varies with regard to age, gender, and their location in the body. Objectives: This study aimed to evaluate the frequency of benign and malignant salivary gland tumors in patients referred to three referral hospitals in Tehran, Iran. Methods: This retrospective cross-sectional study examined the demographic and pathologic records of the patients with salivary gland tumors submitted to the Department of Pathology of Amir Alam, Loghman Hakim, and Shohada Hospitals from 2005 to 2016. In this study, the histological variants of salivary gland tumors and clinical parameters such as age, gender, and the location of the tumor were examined. The clinical data were analyzed using SPSS software version 21. Results: Of 137632 patient records, 1180 cases were salivary gland tumors. Pleomorphic adenoma in 794 cases (67.3%) and adenoid cystic carcinoma in 109 cases (9.2%) were the most common tumors, respectively. Salivary gland tumors were more common in males, and the participants’ mean age was 42.86 ± 16.5 years. The most common site was parotid and minor salivary glands, with 937 (79.4%) and 137 (12%) cases, respectively. Conclusions: In this study, the most common benign tumor was pleomorphic adenoma in the parotid gland, and the most common malignant tumor was adenoid cystic carcinoma in the major salivary glands. Furthermore, benign tumors were more frequent than malignant tumors.

scholarly journals Leiomyosarcoma of Prostate

2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Abdeljalil Heddat ◽  
Younes Houry ◽  
Redouane Rabii
Keyword(s):  
Therapeutic Approach ◽  
Multidisciplinary Approach ◽  
Malignant Tumors ◽  
Survival Rates ◽  
Multicenter Trial ◽  
Advanced Stage ◽  
Rare Tumor ◽  
Actuarial Survival ◽  
Term Survival

Prostate leiomyosarcoma is an extremely rare and very aggressive neoplasm that represents less than 0.1% of primary malignant tumors of the prostate. We present a patient with primary leiomyosarcoma of  prostate and examine the cases reported in the literature to discuss the clinical, diagnostic and therapeutic aspects of this rare tumor. Median survival was estimated at 17 months (95% CI 20.7–43.7 months) and the actuarial survival rates at 1, 3 and 5 years were 68%, 34% and 26%, respectively. The only predictors of long-term survival were negative surgical margins and the absence of metastatic disease at presentation. A multidisciplinary approach is necessary for the proper management of this terrible entity. Surgery with or without chemotherapy seems to be the main therapeutic method for operable leimyosarcomas, but in general there is no consensus on the best therapeutic approach. Most cases are diagnosed at an advanced stage of the disease. A global multicenter trial is needed to find therapies that would improve the prognosis.

Dendritic Interstitial and Myofibroblastic Cells at the Border of Salivary Gland Tumors

2001 ◽  
Vol 125 (2) ◽  
pp. 232-236
Author(s):  
Lori Soma ◽  
Virginia A. LiVolsi ◽  
Zubair W. Baloch
Keyword(s):  
Smooth Muscle ◽  
Salivary Gland ◽  
Malignant Tumors ◽  
Smooth Muscle Actin ◽  
Staining Intensity ◽  
Interstitial Cells ◽  
Salivary Gland Tumors ◽  
Benign Tumors ◽  
Low Grade ◽  
Muscle Actin

Abstract Objective.—CD34-positive dendritic interstitial cells may be associated with the regulation of tumor growth. This association has been studied in various human neoplasms, especially skin tumors. In this study, we evaluated the distribution of dendritic interstitial cells and myofibroblastic cells at the tumor periphery of various benign and malignant salivary gland neoplasms. Methods.—Forty-nine cases of salivary gland tumors were selected: 16 pleomorphic adenomas, 12 Warthin tumors, 8 polymorphous low-grade tumors, 5 adenoid cystic carcinomas, 6 acinic cell carcinomas, and 2 mucoepidermoid carcinomas. Immunohistochemical analysis was performed by using antibodies for CD34 (dendritic cells) and α-smooth muscle actin (myofibroblast) on formalin-fixed, paraffin-embedded archival tissue. Staining intensity was graded as marked (3+), moderate (2+), weak (1+), and absent (0). Results.—Staining intensity for CD34 was 3+ in 24 (86%) of 28 benign tumors (pleomorphic adenomas and Warthin tumors) and 6 (29%) of 21 malignant tumors (polymorphous low-grade tumors, acinic cell carcinomas, adenoid cystic carcinomas, and mucoepidermoid carcinomas) and 2+ in 4 (19%) of 21 malignant tumors. None of the benign tumors displayed 2+ staining with CD34. Three (11%) of 28 benign and 11 (52%) of 21 of malignant tumors failed to stain with CD34. α-Smooth muscle actin staining was 3+ in 10 (36%) of 28 benign tumors and 6 (29%) of 21 malignant tumors, and 2+ in 11 (39%) of 28 benign and 2 (9%) of 21 malignant tumors. Five (18%) of 28 benign and 11 (52%) of 21 malignant tumors failed to stain with α-smooth muscle actin. Conclusion.—We conclude that the dendritic interstitial cells and myofibroblastic cells may be associated with the regulation of tumor growth in salivary gland tumors.

Human Kallikrein 14 (Klk14) Expression in Salivary Gland Tumors

2010 ◽  
Vol 25 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Nelly N. Hashem ◽  
Thomas W. Mara ◽  
Mohamed Mohamed ◽  
Irene Zhang ◽  
Kevin Fung ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Salivary Glands ◽  
Malignant Tumors ◽  
Expression Profiles ◽  
Staining Technique ◽  
Tumor Stage ◽  
Salivary Gland Tumors ◽  
Immunoperoxidase Staining ◽  
Clinical Parameters ◽  
Ductal Cells

Objective To analyze the expression of human kallikrein 14 (KLK14) in salivary gland tumors. Methods A standard immunoperoxidase staining technique was used to assess the expression profile of KLK14 in normal salivary glands and tumors including pleomorphic adenoma (PA; n=17), adenoid cystic carcinoma (ACC; n=13) and mucoepidermoid carcinoma (MEC; n=9). Tumor stage, grade, patient age and gender, and site of occurrence were recorded. These clinical parameters were correlated with KLK14 levels in malignant tumors. The expression profiles for KLK3, 5, 6, 8 and 13 were also retrieved. Results Normal salivary glands, PA, ACC and MEC showed strong expression of KLK14 in ductal and non-ductal cells. Both PA and ACC showed higher KLK14 levels than normal glands and MEC tissues. There were no statistically significant associations between levels of KLK14 and clinical parameters. Conclusions The differences in the levels of KLK14 suggest that KLKs may aid in the differential diagnosis of salivary gland tumors. The coexpression of KLKs suggests their possible involvement in an enzymatic pathway activated in salivary gland. KLK14 may be a promising new biomarker in salivary gland tumors.

scholarly journals Primary Salivary Gland Tumors- A two years study at Nobel Medical College

2019 ◽  
Vol 2 (2) ◽  
pp. 234-238
Author(s):  
Niraj Nepal ◽  
Prabesh Kumar Choudhary ◽  
Manish Kumar Das ◽  
Meenakshi Basnet ◽  
Sagar Paudel
Keyword(s):  
Salivary Gland ◽  
Pleomorphic Adenoma ◽  
Mucoepidermoid Carcinoma ◽  
Malignant Tumors ◽  
Age Groups ◽  
Salivary Gland Tumor ◽  
Salivary Gland Tumors ◽  
Parotid Glands ◽  
Gland Tumor ◽  
Medical College

Introduction: Salivary gland tumors are a heterogeneous group of neoplasms that are relatively rare but represent a wide variety of both benign and malignant histopathologic subtypes. The aim of this study was to find out the histopathological distribution of primary salivary gland tumors and correlate fine needle aspiration cytology reports with histological findings.Materials and Methods: A total of 83 patients attending the otorhinolaryngology department with salivary gland tumors were enrolled in our study. The histopathological findings were reported and correlated with cytological findings.Results: The mean age of the patient with salivary tumors was 43.11 ± 13.02 years. Out of 83 cases, 3 (3.6%) patients were diagnosed as inflammatory lesions, 64 (77.1%) patients had benign salivary gland tumors and 16 (19.3%) of patients had malignant salivary glands tumors in histopathology. The sensitivity and specificity of FNAC in this series for detecting salivary gland malignancy were 68.8% and 98.5% respectively with an overall diagnostic accuracy of 92.8%. The most common salivary gland tumor was found to be pleomorphic adenoma (56.6%) and the most common malignant salivary gland tumor was found to be mucoepidermoid carcinoma (19.3%). The comparison of the incidence of salivary gland tumors in various age groups showed a statisticallysignificant difference (p=0.009).  Conclusions: Benign salivary tumors are more common than malignant tumors with the most common occurrence in parotid glands. Pleomorphic adenoma is the most common benign tumor whereas; mucoepidermoid carcinoma is the most common malignant tumor in patients visiting Nobel medical college.

Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin

2018 ◽  
pp. 574-578 ◽  
Author(s):  
Hagop Kantarjian ◽  
Elias Jabbour
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Pediatric Population ◽  
Lymphoblastic Leukemia ◽  
Treatment Strategies ◽  
Clinical Activity ◽  
Inotuzumab Ozogamicin ◽  
Term Survival ◽  
Drug Conjugates ◽  
Cure Rates

Monoclonal antibodies and bispecific antibody constructs hold considerable promise in improving the outcomes of patients with acute lymphoblastic leukemia (ALL). Antibody-drug conjugates such as inotuzumab ozogamicin and the bispecific T-cell engager blinatumomab represent novel antibody constructs that have shown substantial clinical activity in ALL. Although most studies have focused on the use of these agents in the salvage setting, incorporation of these antibodies into the frontline regimens is imperative to improve long-term survival for patients with ALL and to increase the cure rates of adult ALL to the levels achieved in the pediatric population.

The value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in salivary gland tumors.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17592-e17592
Author(s):  
Idris Yucel ◽  
Ozgur Kemal ◽  
Yasemin Kemal ◽  
Ayse Bel ◽  
Ugur Yildirim ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Malignant Tumors ◽  
Hematological Parameters ◽  
Salivary Gland Tumor ◽  
Salivary Gland Tumors ◽  
Neutrophil To Lymphocyte Ratio ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Inflammatory Parameters ◽  
Tumor Group

e17592 Background: Salivary gland tumors are rare, comprising only 6 to 8 percent of head and neck neoplasms. Most of them are benign and commonly occur in the parotid gland. In the last decade elevated hematological inflammatory parameters like neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were identified as predictive and prognostic factors in various malignancies. The aim of this study was to evaluate the differences of preoperative of NLR and PLR levels in benign and malignant causes of salivary gland tumors. Methods: This retrospective study was made of a total of 133 patients with salivary gland tumors (age range: 17-89 years; 68 male and 65 female) who were treated between January 2006 and May 2016. Preoperative counts and levels of hematological parameters were obtained from the recorded computerized database in benign and malignant tumors. Results: NLR and PLR levels were significantly higher in the malignant salivary gland tumor group than the benign group( NLR: 0.66±1.3 vs 0.59±0.31 p=0.001, PLR: 160.3±85.7 vs 124.6±44.1 p=0.014). Conclusions: The results of the current study revealed the potential predicitve role of NLR and PLR in patients with salivary gland tumors. These cheap and easily available blood count parameters could be useful biomarkers in the future; but further investigations are needed to confirm our findings. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document